Tech Company Financing Transactions
Third Arc Bio Funding Round
Third Arc Bio closed a $52 million Series A funding round on 2/4/2026. Investors included Andreessen Horowitz and private investors.
Transaction Overview
Company Name
Announced On
2/4/2026
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
Andreessen Horowitz (Lead Investor) (Jorge Conde)
Proceeds Purpose
The company intends to use the funds to accelerate its I&I portfolio and deliver additional oncology programs into the clinic.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
888 Boylston Street 1111
Boston, MA 02199
USA
Boston, MA 02199
USA
Phone
Undisclosed
Website
Email Address
Overview
Our mission is to deliver transformational therapies for solid tumors and I&I diseases in the form of multifunctional antibodies that create immune synapses to precisely activate or inhibit T cells. We have a world class team with a proven track record of success, which positions us well to advance the next generation of highly innovative medicines that redefine the standard-of-care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Lebowitz
Chief Operating Officer
Joseph Erhardt
Chief Scientific Officer
Sanjaya Singh
VP - Bus. Development
Debi Watson
Browse more venture capital transactions:
Prev: 2/4/2026: VillageSQL venture capital transaction
Next: 2/4/2026: GenLogs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs